Clinical Trials Logo
  1. Home
  2. Reflux Esophagitis
  3. NCT01538849

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Reflux Esophagitis Clinical Trial

Official title:
Randomized, Double-blind, Active-controlled, Multi-center Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Clinical Trial Summary

This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.

Clinical Trial Description

In the result of recent meta-analysis, there was no improvement in symptoms with the first administration of PPI in about 75% of GERD patients, and symptoms were still sustained in about 50% of patients after administration of more than 3 days. Especially the nocturnal secretion of gastric acid was not effectively inhibited, and about 25% of GERD patients could not achieve the proper therapeutic effects even after PPI treatment twice daily for 4-8 weeks.

YH4808, as a selective K+- competitive acid blocker (P-CAB), is no need for activation by gastric acid since it competitively inhibits proton pump with K+. Thus, the inhibition of gastric acid secretion by YH4808 is prompt and effective. In addition, the inhibitive effect of gastric acid secretion by stimulation of histamine is proved to be more powerful than PPI (esomeprazole) and sustained in in-vitro/in-vivo model, and 24-h inhibition of gastric acid secretion and especially nocturnal inhibition of gastric acid secretion was observed to be superior to esomeprazole with repeat doses for 7 days in healthy volunteers.

Based on these nonclinical and clinical outcomes, an exploratory phase-II clinical trial is to be conducted to determine the proper treatment dose and administration method of YH48084 for GERD patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01538849
Study type Interventional
Source Yuhan Corporation
Contact
Status Completed
Phase Phase 2
Start date December 2012
Completion date May 2014
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06170060 - Treatment of Reflux With Sleeve Gastrectomy N/A
Not yet recruiting NCT06062225 - Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Not yet recruiting NCT06056973 - Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis Phase 4
Completed NCT01008696 - An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Phase 4
Recruiting NCT05899491 - Role of ARMA in Selective Subset of Refractory GERD Patients. N/A
Recruiting NCT01311908 - Incidence of Reflux Esophagitis After Pancreaticoduodenectomy N/A
Completed NCT03214081 - Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Not yet recruiting NCT01560598 - Adipokines and the Risk of Reflux Esophagitis N/A
Completed NCT00859287 - Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis N/A
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Recruiting NCT04657848 - Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy N/A
Completed NCT02477475 - Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes N/A
Completed NCT03553563 - A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Phase 3
Completed NCT01381991 - The Efficacy of i-Scan for Detecting Reflux Esophagitis N/A
Completed NCT04673643 - Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis N/A
Recruiting NCT04531475 - Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis Phase 2
Completed NCT00634114 - Reflux Esophagitis Phase III Study (Maintenance Treatment) Phase 3
Completed NCT00586963 - Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis N/A
Completed NCT03388047 - Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus N/A